JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Home・Aandelen Lijst・Avita Therapeutics Inc

Avita Therapeutics Inc

Gesloten

4.65 -1.9

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.59

Max

4.8

Belangrijke statistieken
By Trading Economics
Inkomsten	1.6M -12M
Verkoop	554K 18M
Winstmarge	-65.968
Werknemers	226
EBITDA	1.6M -9.7M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+32.7% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	30M 153M
Vorige openingsprijs	6.55
Vorige sluitingsprijs	4.65

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

8.83 / 9.77 Steun & Weerstand

Avita Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 apr 2026, 23:33 UTC

Winsten

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 apr 2026, 22:40 UTC

Winsten

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 apr 2026, 22:10 UTC

Acquisities, Fusies, Overnames

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 apr 2026, 21:11 UTC

Winsten

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 apr 2026, 21:01 UTC

Winsten

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 apr 2026, 23:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

22 apr 2026, 23:46 UTC

Marktinformatie

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 apr 2026, 23:34 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 apr 2026, 23:16 UTC

Winsten

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 apr 2026, 23:15 UTC

Winsten

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 apr 2026, 22:54 UTC

Winsten

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 apr 2026, 22:54 UTC

Winsten

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 apr 2026, 22:52 UTC

Winsten

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 apr 2026, 22:51 UTC

Winsten

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 apr 2026, 22:31 UTC

Winsten

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 apr 2026, 22:31 UTC

Winsten

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 apr 2026, 22:30 UTC

Winsten

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 apr 2026, 22:30 UTC

Winsten

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 apr 2026, 22:29 UTC

Winsten

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 apr 2026, 22:28 UTC

Winsten

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 apr 2026, 22:28 UTC

Winsten

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 apr 2026, 22:27 UTC

Winsten

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 apr 2026, 22:06 UTC

Marktinformatie

Winsten

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 apr 2026, 21:55 UTC

Acquisities, Fusies, Overnames

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 apr 2026, 21:47 UTC

Winsten

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 apr 2026, 21:37 UTC

Winsten

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 apr 2026, 21:34 UTC

Winsten

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 apr 2026, 21:29 UTC

Winsten

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 apr 2026, 21:20 UTC

Marktinformatie

Winsten

Tesla Expands Manufacturing to Chips -- Market Talk

Peer Vergelijking

Prijswijziging

Avita Therapeutics Inc Prognose

Koersdoel

By TipRanks

32.7% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.33 USD 32.7%

Hoogste 10 USD

Laagste 3.5 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avita Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Avita Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

8.83 / 9.77Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.